Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minute

The Abbott ID NOW™ COVID-19 test brings rapid testing to the front lines

- Test to run on Abbott's point-of-care ID NOW platform - a portable instrument that can be deployed where testing is needed most

- ID NOW has the largest molecular point-of-care installed base in the U.S. and is available in a wide range of healthcare settings

- Abbott will be making ID NOW COVID-19 tests available next week and expects to ramp up manufacturing to deliver 50,000 tests per day

- This is the company's second test to receive Emergency Use Authorization by the FDA for COVID-19 detection; combined, Abbott expects to produce about 5 million tests per month

https://abbott.mediaroom.com/2020-03-27-Abbott-Launches-Molecular-Point-of-Care-Test-to-Detect-Novel